-
Nerandomilast opens the door for potential monotherapy, add-on therapy for pulmonary fibrosis
Positive results from the FIBRONEER trials of nerandomilast in IPF and PPF have sent the phosphodiesterase 4B inhibitor to the FDA for marketing approval. If approved, nerandomilast would be the first new antifibrotic agent for ILD in more than a decade.
Recent News
-
Beyond the pump: Clinical and psychosocial dimensions of LVAD therapy
Advanced HFrEF carries high mortality, but LVAD therapy can improve survival, heart function, and quality of life.
-
Current standards in donor lung procurement and preservation
Review the American Association for Thoracic Surgery’s expert consensus guidelines for improving standardization in key areas of lung acquisition.
-
Looking ahead to CHEST 2025 in Chicago
CHEST President John Howington, MD, MBA, FCCP, hopes you will join him at CHEST 2025 as we come together to hear the latest advancements in the field and celebrate the remarkable milestone of 90 years of CHEST.
-
Top reads from the CHEST journal portfolio – September 2025
Editorial Board members share their insights on the association between mucus plugs and exacerbations, abnormal pediatric airways, and the association of central nervous system-related biomarkers with delirium.
-
Tezepelumab found to reduce oral corticosteroid use in severe asthma
The WAYFINDER study shows a clinically meaningful reduction in oral corticosteroid dosing, which may allow patients to get off steroids, said pulmonology expert Stephen T. Doyle, DO, MBA, FCCP.
-
New data confirms ILD as lung cancer risk factor
Bradford C. Bemiss, MD, and Claudia Henschke, PhD, MD, said the study clearly shows patients with interstitial lung disease have an increased risk of lung cancer.
